Lexaria Bioscience 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lexaria Bioscience 's ROA in the third quarter of 2026?
Lexaria Bioscience Corp recorded a cumulative net loss of $-8 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -155.59%.

However, within the Healthcare sector 814 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the May 31 2026 quarter, so far to 4451, from total ROA ranking in the second quarter of 2026 at 5156.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(May 31 2026) III. Quarter	(Feb 28 2026) II. Quarter	(Nov 30 2025) I. Quarter	(Aug 31 2025) IV. Quarter	(May 31 2025) III. Quarter
Y / Y Total Assets Change	-28.43 %	-25.06 %	-52.54 %	-52.54 %	-32.07 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-10	-11	-12	-11
Return On Assets (TTM)	-155.59 %	-174.73 %	-179.85 %	-165.91 %	-136.5 %
LEXX's Total Ranking	# 4451	# 5156	# 4549	# 4566	# 4533
Total Assets (TTM) in million	5	7	4	4	7
Seq. Total Assets Change	-25.66 %	54.54 %	0 %	-37.71 %	-22.15 %
Seq. Net Income Change	-	-	-	-	-

LEXX's 5 Years Annual ROA >> Back to LEXX Management Effectiveness >> Compare LEXX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 387
Sector	# 815
Overall	# 4367

Return On Assets Statistics
High	Average	Low
-41.14 %	-135.02 %	-257.78 %
(Aug 31 2021)		(Nov 30 2018)

Financial Statements
Lexaria Bioscience 's Assets	$ 5 million	LEXX's Balance sheet
Lexaria Bioscience 's Income	$ -2 million	Quarterly LEXX's Income Statement
LEXX's Income by Division		See LEXX's Income by Division

Annual Return On Assets	(Aug 31 2025) FY 2025	(Aug 31 2024) FY 2024	(Aug 31 2023) FY 2023	(Aug 31 2022) FY 2022	(Aug 31 2021) FY 2021
Y / Y Total Assets Change	-52.54 %	189.61 %	-60.63 %	-40.95 %	369.09 %
Total Assets in million	4	9	3	8	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-12	-6	-7	-7	-4
Annual Return On Assets	-280.98 %	-65.04 %	-217.66 %	-91.33 %	-29.15 %

LEXX's 5 Years Annual ROA >> Back to LEXX Management Effectiveness >> Compare LEXX ROA to its Competitors

More Return On Assets Ratios
LEXX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LEXX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LEXX's Competitors
Subscribers only: Roa for Lexaria Bioscience 's Suppliers
Subscribers only: Return On Assets for LEXX's Customers

You may also want to know
LEXX's Roi	LEXX's Inventory Turnover Ratio	LEXX's Growth Rates	LEXX's Dividend Comparisons
	LEXX's Profitability Ratios	LEXX's Asset Turnover Ratio	LEXX's Dividend Growth
LEXX's Roe	LEXX's Valuation Ratios	LEXX's Financial Strength Ratios	LEXX's Dividend Payout Ratio

Companies with similar Return On Assets at May 31 2026, within Healthcare Sector

ROA

Date modified: 2026-08-03T18:30:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.